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التحليل اجلزيئي حلالة خلل التنسج املميت يكشف عن طفرتني مغلوطتني 
جديدتني جلني FGFR3 تقعان على السيس
رينات مرق�ض نيكل�صون، �صامل افتيمو�ض، دونالد ر لوف
امللخ�ص: الهدف: ان خلل التن�صج املميت هو اأكرث اأنواع خلل التن�صج الهيكلي القاتل �صيوعا وينتج عن �صقة ج�صمية �صائدة ويتميز بوجود 
كرب يف حجم الراأ�ض، �صيق يف حجم ال�صدر، اأ�صلع ق�صرية، اأ�صابع ق�صرية و ارتخاء يف الع�صالت. وبالإ�صافة اإىل هذه املالمح الظاهرية 
الثاين ب�صغر الأطراف وا�صتقامة  النوع  الفخذ بينما يتميز  النوع الأول من هذا املر�ض ب�صغر الأطراف وانحناء عظام  اجلوهرية فيتميز 
عظام الفخذ ووجود ت�صوه بر�صيمي يف �صكل اجلمجمة. من املعروف اأن كل حالت هذا املر�ض تنتج عن طفرات يف جني ال ف ج ف ر3. 
هدفت الدرا�صة ايل التعرف على طيف الطفرات امل�صوؤوله عن حدوث هذا املر�ض. طرق الدرا�صة: مت ا�صتخدام تفاعل البلمرة ال�صل�صلي التقليدي 
والأليلي والتحليل الت�صل�صلي لتحديد طفرات جني ال ف ج ف ر3 يف جنني م�صاب بخالل التن�صج املميت والذي مت اكت�صافة اثناء احلمل 
با�صتخدام املوجات فوق ال�صوتية. النتائج: يف هذا البحث ن�صتعر�ض كيفية حتديد طفرتني مغلوطتني جديدتني جلني ال ف ج ف ر3 تقعان 
على ال�صي�ض يف جنني لديه العالمات الظاهرية ملر�ض خلل التن�صج املميت. اخلال�صة: هذه هي املرة الثانية التي يتم فيها و�صف حالة خلل 
التن�صج املميت نتيجة لوجود طفرتني مغلوطتني جديدتني جلني ال ف ج ف ر3 تقعان على ال�صي�ض مما يدل على اأن طيف الطفرات امل�صببة 
لهذا املر�ض قد يكون اكرث �صيوعا مما هو معتقد.  
مفتاح الكلمات: خلل التن�صج املميت،  جني ف ج ف ر3، خلل التن�صج الهيكلي، تفاعل البلمرة ال�صل�صلي الأليلي.
abstract: Objectives: Thanatophoric dysplasia (TD) is the most common form of lethal skeletal dysplasia. It 
is primarily an autosomal dominant disorder and is characterised by macrocephaly, a narrow thorax, short ribs, 
brachydactyly, and hypotonia. In addition to these core phenotypic features, TD type I involves micromelia with 
bowed femurs, while TD type II is characterised by micromelia with straight femurs and a moderate to severe 
clover-leaf deformity of the skull. Mutations in the FGFR3 gene are responsible for all cases of TD reported to date. 
The objective of the study here was to delineate further the mutational spectrum responsible for TD. Methods: 
Conventional polymerase chain reaction (PCR), allele-specific PCR, and sequence analysis were used to identify 
FGFR3 gene mutations in a fetus with a lethal skeletal dysplasia consistent with TD, which was detected during 
a routine antenatal ultrasound examination. Results: In this report we describe the identification of two de novo 
missense mutations in cis in the FGFR3 gene (p.Asn540Lys and p.Val555Met) in a fetus displaying phenotypic 
features consistent with TD. Conclusion: This is the second description of a case of TD occurring as a result of 
double missense FGFR3 gene mutations, suggesting that the spectrum of mutations involved in the pathogenesis of 
TD may be broader than previously recognised.
Keywords: Thanatophoric dysplasia; FGFR3; Skeletal dysplasia; Allele-specific PCR.
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Advances in Knowledge
- This study is only the second report in which the mutations in the FGFR3 gene differ from those classically implicated in the development 
of thanatophoric dysplasia (TD). 
Applications to Patient Care
- The findings suggest that confirmation of a clinical diagnosis of thanatophoric dysplasia should include a comprehensive screen for 
mutations in all coding exons of the FGFR3 gene, particularly in the absence of one of the classic TD mutations.
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Thanatophoric dysplasia (TD) is the most common form of lethal short-limb skeletal dysplasia with a prevalence 
of approximately 2/100,000 births.1 It was first 
described as thanatophoric dwarfism by Maroteaux 
and Lamy in 1967, undergoing a name change in 
1977 as a result of a decision reached at the 2nd 
International Conference on the Nomenclature of 
Skeletal Dysplasias.2 It is characterised by a range 
of phenotypic features, foremost among which 
are macrocephaly, a narrow thorax, short ribs, 
brachydactyly, and micromelia.3 There are two forms 
of TD, designated TD type I and TD type II, which 
can be differentiated principally by the presence of 
bowed, rather than straight, femurs in TD type I 
and of a moderate to severe clover-leaf deformity of 
the skull in TD type II.3 A clover-leaf skull deformity 
may also occur in TD type I but is infrequent and 
less severe than in TD type II.3 Both subtypes of 
TD are considered lethal with most affected infants 
dying as a result of respiratory insufficiency within 
the first few hours of life; however, there are reports 
of a small number of affected individuals who have 
survived into childhood by virtue of aggressive 
ventilatory support.4
As with the other severe skeletal dysplasias, TD 
is frequently diagnosed following a routine antenatal 
ultrasound screening in the first or second trimester. 
The earliest radiological signs are increased nuchal 
thickness and short limbs, but these signs are non-
specific.5,6 A molecular diagnosis may be made 
prenatally if genetic testing for TD is requested 
on deoxyribonucleic acid (DNA) extracted from 
a chorionic villus or amniocentesis sample, but is 
more commonly made following a post-mortem 
examination carried out to clarify the nature of the 
lethal skeletal dysplasia in question.5,6 
TD is primarily an autosomal dominant 
disorder, resulting from heterozygous mutations 
in the FGFR3 gene that lead to ligand-independent 
activation of the receptor and disruption of 
cartilage function during linear bone growth.7 
Mutations in the FGFR3 gene cause a spectrum of 
skeletal dysplasias ranging from the relatively mild 
hypochrondroplasia through to achondroplasia, 
severe achondroplasia with developmental 
delay and acanthosis nigricans (SADDAN), and 
thanatophoric dysplasia.7 As expected from the 
severity of the disorder, the majority of TD-related 
mutations in the FGFR3 gene are de novo and 
the recurrence risk for parents with a previously 
affected pregnancy is very low, particularly if both 
parents are phenotypically normal.3 A single case 
of somatic and germline mosaicism for the TD 
type 1 mutation Arg248Cys has been described.8 
The mosaic individual in this instance was affected 
by a disproportionate asymmetric rhizomelic 
shortening of the limbs. Her only pregnancy was 
complicated by severe pre-eclampsia and resulted 
in the stillbirth of an infant with a phenotype 
consistent with TD.8 
We present here a case in which TD was 
diagnosed prenatally by ultrasound scanning 
and describe the results of subsequent molecular 
analysis, which revealed a double de novo mutational 
event.
Methods
Informed consent was provided by the parents of the 
proband reported here; the proband was studied at 
the genetic level to confirm a clinical diagnosis of TD. 
The New Zealand multi-region ethics committee 
has ruled that cases of patient management do not 
require formal ethics committee approval.
A skin biopsy from the affected fetus was taken 
at autopsy and the tissue was cultured according 
to conventional cytogenetic techniques. Genomic 
DNA (gDNA) was isolated from the cultured cells 
by phenol/chloroform extraction and ethanol 
precipitation. In the case of peripheral blood in 
ethylenediaminetetraacetic acid (EDTA), gDNA was 
isolated using the Gentra Puregene DNA Extraction 
kit (Qiagen Pty Ltd, Doncaster, Australia).
The messenger ribonucleic acid (mRNA) 
sequence of transcript 1 of the FGFR3 gene was 
identified using the University of California Santa 
Cruz (UCSC) genome browser.9 This website 
provides a direct link to ExonPrimer for the design 
of primers flanking coding exons. The first coding 
exon of transcript 1 of the FGFR3 gene is exon 
2, so primers were not designed against exon 1. 
ExonPrimer is a Perl script that uses a combination 
of Primer3 and Blat to design intronic primers 
against a complementary DNA (cDNA) of interest. 
Default parameters were used. The coverage (entire 
coding exon and at least 20 bp of flanking intronic 
sequence to allow interrogation of splice sites) and 
specificity of the primers were confirmed using the 
in-silico polymerase chain reaction (PCR) tool also 
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available on the UCSC genome browser. All primers 
were checked for single nucleotide polymorphisms 
using the software tool available from the 
National Genetic Reference Laboratory, 
Manchester, UK.10 The primers were tailed with 
M13 sequences for ease of subsequent sequence 
analysis, and were synthesised by Invitrogen Ltd., 
(Renfrewshire, UK) [Table 1]. 
We used the freely accessible online tetra-
primer amplification refractory mutation system 
(ARMS)-PCR primer design programme11 to 
design allele-specific PCR primers to target the 
DNA variants of interest.12 Specificity is ensured 
by not only using allele-specific primers with 
differing 3' terminal bases but also including an 
additional mismatched base at position -2 from 
the 3' end. Two pairs of primers were designed. 
Each pair contained one allele-specific primer that 
would result in amplification of only the wild-type 
allele of each of the two variants in question. The 
other primer in each pair was positioned such that 
the second variant was also included within the 
amplicon, thereby allowing the phase of the variants 
to be determined. These two additional primer pairs 
were likewise tailed with M13 sequences and were 
synthesised by Invitrogen Ltd. (Renfrewshire, UK).  
Conventional and allele-specific PCR were 
performed using 1U Faststart Taq DNA polymerase 
(Invitrogen Ltd, Renfrewshire, UK), 50 ng genomic 
DNA, 2mM MgCl2, and 0.8 μM forward and reverse 
primers with the following cycle conditions: 95° C 
for 4 minutes, 35 cycles of 94° C for 45 seconds, 
60° C for 30 seconds, 72° C for 30 seconds, and a 
final extension at 72° C for 10 minutes. All amplicons 
amplified efficiently under these conditions.
An amount of 5 µL of each PCR was cleaned with 
Table 1: Primers for the amplification of all coding exons of the FGRF3 gene (Refseq accession number 
NM_000142.4)








































































Blue and red coloured bases represent M13 sequences that tail the forward and reverse primers.
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ExoSAP-IT (Affymetrix, Santa Clara, California, 
USA) prior to bidirectional DNA sequencing using 
M13 forward and reverse primers and Big-Dye 
Terminator, Version 3.0 (Applied Biosystems Ltd., 
Carlsbad, California, USA). An amount of 20 µL of 
sequenced product was purified using an automated 
Agencourt CleanSEQ (Agencourt Bioscience Corp., 
Beverly, Massachusetts, USA) procedure with the 
aid of an epMOTION 5075 liquid handling robot 
(Eppendorf, Hamburg, Germany). An amount 15 µL 
of purified product was then subjected to capillary 
electrophoresis using an Applied Biosystems model 
3130xl genetic analyser.
The analysis of sequence traces was performed 
using Variant Reporter, Version 1.0 (Applied 
Biosystems). Genebank NM_000142.4 was used 
as the reference sequence, with cDNA number 
+1 corresponding to the A of the translation 
initiation codon. Amino acid numbering began at 
the first amino acid in RefSeq accession number 
NP_000133.1. Exons were numbered sequentially, 
with exon 2 being the first exon analysed (exon 1 
is non-coding). Variant Reporter uses advanced 
algorithms and quality metrics to automate the 
detection of variants and to streamline the analysis 
process. Traces produced from the sequencing 
of allele-specific PCR amplicons were analysed 
manually.
Results
The fetus was the third child to non-consanguineous 
parents. The first antenatal ultrasound scan at 13 
weeks gestation demonstrated a nuchal thickness 
of 2.0 mm. The second ultrasound at 19 weeks 
was technically very difficult because of fetal lie 
and maternal habitus. However, it demonstrated 
the presence of a grossly enlarged skull with an 
abnormal shape (biparietal diameter [BPD] 59 mm, 
head circumference [HC] 207 mm). The fetal chest 
was subjectively small and the limbs were short with 
both femoral length (FL) and humeral length (HL) 
well below the 5th centile (FL 22 mm; HL 19 mm). 
These findings were indicative of a lethal skeletal 
dysplasia. The parents were counselled accordingly 
and decided to proceed with a termination which 
was performed at 19 weeks and 5 days’ gestation.
Skeletal radiographs [Figure 1] showed a narrow 
thorax in both anteroposterior and lateral views. 
The skull was large in relation to the facial bones 
and abnormally shaped but without a clover-leaf 
appearance. The vertebral bodies were flat with 
an H-shaped appearance but no notching of the 
central portions of the upper and lower plates. 
There was narrowing of the lumbar interpediculate 
distances from L1–L3. The long bones were short 
and relatively broad with mild bowing of the 
femora. The metaphyseal regions were cupped and 
flared. The pelvic bones were short and broad with 
horizontal inferior margins of the iliac bones. 
 
Figure 1: Fetal phenotype: skeletal radiographs of anteroposterior (I), lateral (II) and pelvic (III) views.
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Overall, the radiologic findings were consistent 
with TD with an overlap between TD type I and 
TD type II. The vertebral abnormalities were more 
consistent with TD type II, while the mild femoral 
angulation was not characteristic of TD type II, 
but was not as severe as would be expected in TD 
type I.
Conventional PCR and bidirectional sequence 
analysis of all coding exons of the FGFR3 gene in the 
affected fetus detected compound heterozygosity 
for the mutations c.1620C>A (p.Asn540Lys) and 
c.1663G>A (p.Val555Met) in exons 12 and 13, 
respectively, of the FGFR3 gene [Figure 2]. 
In order to determine the phase of these 
mutations, subsequent allele-specific PCR was 
performed [Figure 3]. Sequencing of the amplicons 
produced by allele-specific PCR demonstrated that 
the variants were present in cis [Figure 4].
DNA extracted from the peripheral blood of 
both parents was analysed for the presence of each 
of these variants. Both variants proved to be absent 
in each parent, indicating that they were most 
probably de novo in the fetus (gonadal mosaicism in 
one of the parents has not been excluded).
Discussion
The case we present here exhibits the classic 
phenotypic features of TD with overlapping features 
of type I and type II. Molecular genetic testing for 
TD type I involves either full sequence analysis of 
all coding exons of the FGFR3 gene (as was the 
approach taken in this case), or more targeted 
initial analysis of exons 7, 10, 15, and 19, which are 
the exons containing the mutations responsible for 
99% of cases of TD type I reported to date. This is 
followed by full analysis if no mutation is identified.3 
The mutations themselves can be placed into two 
classes. The first includes the two most common 
TD type I mutations, Arg248Cys and Tyr373Cys, 
and involves the creation of new unpaired cysteine 
residues.3 The second class of pathogenic TD type 
I mutations result in obliteration of the native stop 
codon and addition of a hydrophobic alpha helix-
containing domain to the carboxyl terminus of 
the protein.3 The single mutation known to cause 
TD type II, p.Lys650Gly, destabilises the activation 
loop of the second portion of the split tyrosine 
kinase domain resulting in ligand-independent 
activation.11
 
Figure 2: (Panel A) Fetal genotype: sequence electropherograms show the c.1620C>A (p.Asn540Lys); (Panel B) 
c.1663G>A (p.Val555Met) variants in exons 12 and 13, respectively, of the FGFR3 gene in the affected fetus.
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Neither of the mutations detected in the fetus 
described above fall into these categories. The 
first variant, c.1620C>A (p.Asn540Lys), is present 
in the heterozygote state in approximately 72% of 
individuals with classic hypochondroplasia.14 The 
second variant, c.1663G>A (p.Val555Met), is not 
listed in the online Human Gene Mutation Database 
(HGMD) and does not appear to be reported in 
the literature. Bioinformatic analysis using the 
online prediction tools Polyphen-215 and SIFT16 
suggests that it is highly likely to be of pathogenic 
significance. In addition, valine at position 555 is 
conserved across species.
Compound heterozygosity in trans for 
the Asn540Lys mutation and the Gly380Arg 
mutation that is responsible for 98% of cases of 
achondroplasia17 has been reported.18–21 Individuals 
who are compound heterozygotes for these two 
variants typically display a more severe skeletal 
phenotype than seen in classical achondroplasia, 
but the condition is still compatible with survival, 
unlike the lethal form of achondroplasia that results 
from homozygosity for the Gly380Arg mutation. 
It has been shown that the level of ligand-
independent tyrosine kinase activity is directly 
related to the skeletal phenotype, so it is to be 
expected that the combination of the less-activating 
mutation Asn540Lys and Gly380Arg will result 
in a less severe phenotype than that caused by 
homozygosity for Gly380Arg alone.13
In contrast, a case of apparent TD type I in 
association with compound heterozygosity for 
Asn540Lys and a second previously unreported 
mutation, Gln485Arg, has also been described.22 
In this instance, as in our case, the two FGFR3 
mutations identified were de novo in the affected 
fetus and in cis. Analysis of the deduced X-ray 
crystallographic structure of FGFR3 led the authors 
to postulate that the presence of two mutations in 
cis alters the receptor structure to such an extent 
that it is held in a fully activated state, with each 
mutation attenuating the effect of the other, leading 
to the lethal form of skeletal dysplasia characteristic 
of TD.22
Each of the mutations identified in our fetus 
is located within the first portion of the split 
intra-cellular tyrosine kinase domain.23 It has 
been recognised that the activation of FGFR3 
caused by substitutions within the tyrosine kinase 
domain is due to a mechanism that mirrors the 
conformational changes that are normally a result 
of ligand-mediated FGFR3 dimerisation and 
 
Figure 3: Sequences and primers for allele-specific PCR: allele-specific primer sequences are shown to determine the 
phase of the FGFR3 gene mutations detected in the affected fetus.
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autophosphorylation.23,24 Double mutation alleles 
have been reported in association with a range of 
disorders, often complicating genotype-phenotype 
correlations.25,26 It is probable that the basis of the 
severe phenotype seen in our case, in contrast to 
the phenotype that results from the Asn540Lys 
mutation alone or in combination with Gly380Arg, 
is related to the ‘double-hit’ effect of two mutations 
both acting in this critical region of the protein. It 
is the combination of the location of the mutations 
and the attenuating effect they have upon each 
other that is significant. 
A recent review of the current understanding 
of FGFR3 signalling in the skeletal dysplasias 
concludes that, although progress is being made, 
there are still a large number of questions to be 
answered regarding almost every aspect of the 
action of FGFR3, particularly when it comes to 
cartilage.23 The rate of de novo double mutations 
occurring in the same gene in cis is predicted to be 
very low at approximately,12–13 therefore it is unlikely 
to be a common mechanism in the pathogenesis of 
TD.27
Conclusion
The case we describe is the second report in 
which the mutations differ from those classically 
implicated in the development of TD. Findings such 
as this may be usefully incorporated into the design 
of functional studies in the future, and suggest that 
the range of genotypes potentially responsible for 
the characteristic TD phenotype is likely to be 
broader than previously recognised.
References
1. Martınez-Frıas ML, de Frutos CA, Bermejo E, 
ECEMC Working Group, Nieto MA. Review of the 
recently defined molecular mechanisms underlying 
thanatophoric dysplasia and their potential 
therapeutic implications for achondroplasia. Am J 
Med Genet Part A 2010; 152A:245–55.
2. Schild RL, Hunt GH, Moore J, Davies H, Horwell DH. 
Antenatal sonographic diagnosis of thanatophoric 
dysplasia: A report of three cases and a review of the 
literature with special emphasis on the differential 
diagnosis. Ultrasound Obstet Gynecol 1996; 8:62–7.
3. Karczeski B, Cutting GR. Thanatophoric Dysplasia. 
In: Pagon RA, Bird TD, Dolan CR, et al., Eds. 
 
Figure 4: Sequence electropherograms of allele-specific PCR. (Panel A)Amplicon produced by primers specific for wild-
type allele at c.1663. The red arrow indicates position c.1620—note the apparent homozygosity for wild-type c.1620C. 
(Panel B) Amplicon produced by primers specific for wild-type allele at c.1620. The red arrow indicates position c.1663—
note the apparent homozygosity for wild-type c.1663G.
Renate Marquis-Nicholson, Salim Aftimos and Donald R. Love
brief communication | 87
GeneReviews™. Seattle: University of Washington, 
1993.
4. MacDonald IM, Hunter AG, MacLeod PM, 
MacMurray SB. Growth and development in 
thanatophoric dysplasia. Am J Med Genet 1989; 
33:508–12.
5. Giancotti A, Castori M, Spagnuolo A, Binni F, 
D'Ambrosio V, Pasquali G, et al. Early ultrasound 
suspect of thanatophoric dysplasia followed by first 
trimester molecular diagnosis. Am J Med Genet Part 
A 2011; 155:1756–8.
6. Delahaye S, Rosenblatt J, Costa JM, Bazin A, Bénifla 
JL, Jouannic JM. First-trimester molecular prenatal 
diagnosis of a thanatophoric dysplasia. Prenat Diagn 
2010; 30:1222–3.
7. Hatzaki A, Sifakis S, Apostolopoulou D, Bouzarelou 
D, Konstantinidou A, Kappou D, et al. FGFR3 
related skeletal dysplasias diagnosed prenatally 
by ultrasonography and molecular analysis: 
Presentation of 17 cases. Am J Med Genet Part A 
2011; 155:2426–35.
8. Hyland VJ, Robertson SP, Flanagan S, Savarirayan 
R, Roscioli T, Masel J, et al. Somatic and germline 
mosaicism for a R248C missense mutation in 
FGFR3, resulting in a skeletal dysplasia distinct from 
thanatophoric dysplasia. Am J Med Genet Part A 
2003; 120:157–68.
9. Genome Browser. University of California Santa 
Cruz (UCSC) From: http://genome.ucsc.edu 
Accessed: Apr 2012.
10. National Genetic Reference Laboratory, Manchester, 
UK, Software tool. From: http://ngrl.man.ac.uk/
SNPCheck.html Accessed: Apr 2012.
11. PRIMER1: primer design for tetra-primer ARMS-
PCR. From: http://primer1.soton.ac.uk/primer1.
html Accessed: Apr 2012.
12. Ye S, Dhillon S, Ke X, Collins AR, Day IN. An 
efficient procedure for genotyping single nucleotide 
polymorphisms. Nucl Acids Res 2001; 29:E88. 
13. Bellus GA, Spector EB, Speiser PW, Weaver CA, 
Garber AT, Bryke CR, et al. Distinct missense 
mutations of the FGFR3 lys650 codon modulate 
receptor kinase activation and the severity of the 
skeletal dysplasia phenotype. Am J Hum Genet 2000; 
67:14–21.
14. Francomano CA. Hypochondroplasia. In: Pagon RA, 
Bird TD, Dolan CR, et al., Eds.GeneReviews™. Seattle, 
Washington: University of Washington, 1993.
15. Polyphen-2 prediction tool. From: http://genetics.
bwh.harvard.edu/pph2/index.shtml  Accessed: Apr 
2012.
16. SIFT prediction tool. From: http://sift.jcvi.org/www/
SIFT_enst_submit.html Accessed: Apr 2012.
17. Pauli RM. Achondroplasia. In: Pagon RA, Bird 
TD, Dolan CR, et al., Eds. GeneReviews™. Seattle: 
University of Washington, 1993. 
18. McKusick VA, Kelly TE, Dorst JP. Observations 
suggesting allelism of the achondroplasia and 
hypochondroplasia genes. J Med Genet 1973; 10:11–
16.
19. Sommer A, Young-Wee T, Frye T. Achondroplasia-
hypochondroplasia complex. Am J Med Genet 1987; 
26:949–57.
20. Huggins MJ, Smith JR, Chun K, Ray PN, Shah JK, 
Whelan DT. Achondroplasia-hypochondroplasia 
complex in a newborn infant. Am J Med Genet 1999; 
84:396–400.
21. Chitayat D, Fernandez B, Gardner A, Moore L, 
Glance P, Dunn M, et al. Compound heterozygosity 
for the achondroplasia-hypochondroplasia FGFR3 
mutations: Prenatal diagnosis and postnatal 
outcome. Am J Med Genet 1999; 84:401–5.
22. Pannier S, Martinovic J, Heuertz S, Delezoide AL, 
Munnich A, Schibler L, et al. Thanatophoric dysplasia 
caused by double missense FGFR3 mutations. Am J 
Med Genet Part A 2009; 149A:1296–1301.
23. Foldynova-Trantirkova S, Wilcox WR, Krejci 
P. Sixteen years and counting: The current 
understanding of fibroblast growth factor receptor 3 
(FGFR3) signaling in skeletal dysplasias. Hum Mutat 
2012; 33:29–41.
24. Webster MK, D’Avis PY, Robertson SC, Donoghue 
DJ. Profound ligand-independent kinase activation 
of fibroblast growth factor receptor 3 by the 
activation loop mutation responsible for a lethal 
skeletal dysplasia, thanatophoric dysplasia type I. 
Mol Cell Biol 1996; 16:4081–7.
25. Savov A, Angelicheva D, Balassopoulou A, Jordanova 
A, Noussia-Arvanitakis S, Kalaydjieva L. Double 
mutant alleles: Are they rare? Hum Mol Genet 1995; 
4:1169–71.
26. Blair E, Price SJ, Baty CJ, Östman-Smith I, Watkins H. 
Mutations in cis can confound genotype-phenotype 
correlations in hypertrophic cardiomyopathy. J Med 
Genet 2001; 38:385–423.
27. Kondrashov AS. Direct estimates of human per 
nucleotide mutation rates at 20 loci causing 
mendelian diseases. Hum Mutat 2002; 21:12–27.
